Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Alnylam Pharma (ALNY)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report) and Alnylam Pharma (ALNY – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Telix Pharmaceuticals (TLPPF)
Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company's shares closed last Monday at $17.00.
According to TipRanks.com, Hester is a 4-star analyst with an average return of 4.8% and a 50.6% success rate. Hester covers the Healthcare sector, focusing on stocks such as Paradigm Biopharmaceuticals, Pro Medicus Limited, and Nanosonics Limited.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.88 average price target, representing a 28.7% upside. In a report issued on April 22, TD Cowen also maintained a Buy rating on the stock with a A$35.00 price target.
Alnylam Pharma (ALNY)
TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma today and set a price target of $371.00. The company's shares closed last Monday at $254.85.
According to TipRanks.com, Baral is a 3-star analyst with an average return of 2.0% and a 39.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Milestone Pharmaceuticals, and Sionna Therapeutics, Inc.
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $312.95, a 23.8% upside from current levels. In a report issued on April 15, Evercore ISI also maintained a Buy rating on the stock with a $280.00 price target.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

Couchbase downgraded to Hold from Buy at Truist

Truist downgraded Couchbase (BASE) to Hold from Buy with a price target of $24.50, up from $21, after the company announced an agreement to be acquired by Haveli Investments for $24.50 per share in cash. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

an hour ago

• Business Insider

Trade Desk management to meet virtually with Benchmark

Virtual Meeting to be held on June 26 at 11 am hosted by Benchmark. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

an hour ago

• Business Insider

Lavoro downgraded to Hold from Buy at Canaccord

Canaccord downgraded Lavoro (LVRO) to Hold from Buy with a price target of $2.25, down from $5.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>